Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

被引：137

作者：

van der Heijde, D. ^{[1
]}

Schiff, M. H. ^{[2
]}

Sieper, J. ^{[3
,4
]}

Kivitz, A. J. ^{[5
]}

Wong, R. L. ^{[6
]}

Kupper, H. ^{[7
]}

Dijkmans, B. A. C. ^{[8
,9
]}

Mease, P. J. ^{[10
]}

Davis, J. C., Jr. ^{[11
]}

机构：

[1] LUMC, Dept Rheumatol, NL-2300 RC Leiden, Netherlands

[2] Univ Denver, Denver, CO USA

[3] Free Univ Berlin, Dept Med 1, Benjamin Franklin Hosp, D-1000 Berlin, Germany

[4] German Rheumatism Res Ctr, Berlin, Germany

[5] Altoona Ctr Clin Res, Duncansville, PA USA

[6] Abbott Labs, Parsippany, NJ USA

[7] Abbott GmbH & Co KG, Ludwigshafen, Germany

[8] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, Amsterdam, Netherlands

[9] Jan van Breemen Inst, Amsterdam, Netherlands

[10] Univ Washington, Sch Med, Swedish Med Ctr, Seattle, WA USA

[11] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2009年 / 68卷 / 06期

关键词：

PLACEBO-CONTROLLED TRIAL; ANTITUMOR NECROSIS FACTOR; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CONCOMITANT METHOTREXATE; CLINICAL-TRIALS; INFLIXIMAB; SAFETY; EFFICACY;

D O I：

10.1136/ard.2007.087270

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial. Methods: Patients received adalimumab 40 mg every other week (eow) or placebo for 24 weeks in ATLAS. At week 24, patients were switched to open-label adalimumab 40 mg eow. Efficacy measures included 20% improvement in the Assessment in SpondyloArthritis International Society (ASAS) criteria (ASAS20), ASAS40 and ASAS partial remission responses and changes in individual components of the ASAS20 response evaluations, for example, Bath AS Functional Index (BASFI) and Bath AS Disease Activity Index (BASDAI). Two-year interim data were analysed based on the total duration of adalimumab exposure, irrespective of the treatment randomisation group. Results: At 2 years, 255 (82.0%) of the original 311 ATLAS patients continued receiving adalimumab treatment. Improvements in ASAS responses observed in ATLAS were sustained during long-term treatment; 64.5% (200/310) were ASAS20 responders, 50.6% (157/310) were ASAS40 responders and 33.5% (104/310) had maintained ASAS-defined partial remission. Changes in individual ASAS response components were sustained or improved during long-term adalimumab treatment. From ATLAS baseline to 2 years of adalimumab exposure, respectively, BASDAI improved from 6.3 (SD 1.7) to 2.4 (SD 2.3) and BASFI improved from 5.2 (SD 2.4) to 2.9 (SD 2.5). Adalimumab was well tolerated. No cases of tuberculosis, congestive heart failure, lupus-like symptoms, or demyelinating disease were reported. Conclusions: Adalimumab reduced the signs and symptoms of AS and induced partial remission for up to 2 years. The long-term safety profile was similar to the short-term safety profile. Trial registration information: NCT00085644

引用

页码：922 / 929

页数：8

共 50 条

[1] Long-term adalimumab treatment reduces signs and symptoms in ankylosing spondylitis (AS) patients - Results from the ATLAS trial
Van der Heijde, D.
Kivitz, A.
Schiff, M.
Sieper, J.
Dijkmans, B.
Braun, J.
Dougados, M.
Reveille, J.
Wong, R.
Kupper, H.
Davis, J.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 86 - 87
[2] Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS)
Revicki, Dennis A.
Luo, Michelle P.
Wordsworth, Paul
Wong, Robert L.
Chen, Naijun
Davis, John C., Jr.
JOURNAL OF RHEUMATOLOGY, 2008, 35 (07) : 1346 - 1353
[3] IMPROVEMENT IN LONG-TERM SPINAL MOBILITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) IS SUSTAINED DURING UP TO 3 YEARS OF ADALIMUMAB TREATMENT: 3-YEAR ATLAS RESULTS
Scott, D. G.
van der Heijde, D.
Schiff, M. H.
Sieper, J.
Kivitz, A.
Dijkmans, B. A.
Mease, P. J.
Kupper, H.
Ballal, S.
Wong, R. L.
RHEUMATOLOGY, 2009, 48 : I56 - I56
[4] Adalimumab reduces pain and fatigue in ankylosing spondylitis (AS) patients - Results from the ATLAS trial
Davis, J.
Luo, M. R.
Zeidler, H.
Matsumoto, A.
Dijkmans, B. A. C.
Salvarani, C.
Veys, E.
Wong, R.
Van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 213 - 213
[5] Long-term efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label, 2-year trial
Haibel, H.
Brandt, H. C.
Baraliakos, X.
Rudwaleit, M.
Listing, J.
Braun, J.
Kupper, H.
Sieper, J.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 218 - 219
[6] Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
Sieper, Joachim
van der Heijde, Desiree
Dougados, Maxime
Brown, L. Steve
Lavie, Frederic
Pangan, Aileen L.
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (05) : 700 - 706
[7] Adalimumab treatment maintains efficacy and safety in patients with ankylosing spondylitis (AS)-2-year results from ATLAS
van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 412 - 412
[8] Optical coherence tomography changes in ankylosing spondylitis patients on long-term adalimumab treatment
Yavuz, Nurce Cilesizoglu
Ozer, Murat Atabey
Sari, Ilker Fatih
Kulakli, Sevgi
Tatli, Samet
Ogut, Halil
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2022, 68 (12): : 1626 - 1630
[9] COMPARISON OF LONG-TERM DRUG SURVIVAL OUTCOME WITH ETANERCEPT TREATMENT AND ADALIMUMAB TREATMENT OF ANKYLOSING SPONDYLITIS
Ruwaard, J.
I'Ami, M.
Marsman, A.
Kneepkens, E.
van der Horst-Bruinsma, I. E.
van Denderen, C.
Nurmohamed, M. T.
Wolbink, G.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 813 - 813
[10] Long-term spinal mobility in patients with ankylosin spondylitis (AS) -: 3-year results from the adalimumab (HUMIRA®) trial valuating long-term efficacy and safety in AS (ATLAS)
van der Heijde, Desiree
Schiff, Michael
Sieper, Joachim
Kivitz, Alan
Dijkmans, Ben
Mease, Philip
Kupper, Hartmut
Ballal, Shaila
Wong, Robert
ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S578 - S579

← 1 2 3 4 5 →